Target: CD56.
Clone: ERIC-1.
Specificity: Anti-CD56 In Vivo Antibody - Low Endotoxin (ERIC-1) recognizes Human CD56. Anti-Human CD56 recognizes the (Mr 180, 145, 125 kDa) isoforms of the human neural cell adhesion molecule (NCAM).
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: The CD56 (NCAM) antigen is expressed on most neuroectodermal derived cell lines, tissues, and tumors. NCAM is also known to be expressed on some mesodermally derived tissues such as muscle and on natural killer (NK) lymphocytes. The binding of ERIC-1 to both normal and neoplastic tissue is lost when tissues are conventionally fixed in formalin and embedded in paraffin. The epitope was preserved when exposed to dehydrating fixatives such as cold acetone (-20EC) for 5 min. CD56 is present on 10-25% of peripheral blood lymphocytes.
Background: Anti-Human CD56 can be used in studies of the neural cell adhesion molecule. This antibody may also be used to study isoforms of NCAM expressed on different tumor types. Anti-CD56 (clone ERIC-1) works well in western blot for analysis of isoforms expressed. Anti-CD56 did not react with any of the leukemias or lymphomas tested.
Immunogen: Human Retinoblastoma tumor.
Concentration: 1.0 - 5.0 mg/ml.
Formulation: 0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Purity: >95% by SDS-PAGE and HPLC.
Endotoxin: <0.5 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 5%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.